ArticleFrontiers in cardiovascular medicine2026
Long-term clinical efficacy of Marshall vein ethanol infusion combined with catheter ablation for persistent AF.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent atrial arrhythmia after radiofrequency catheter ablation (RFCA) for persistent atrial fibrillation (AF) necessitates better strategies. Ethanol infusion of the vein of Marshall (EI-VOM) is an emerging adjunct, but long-term efficacy data combined with RFCA is limited. This study compared long-term arrhythmia-free survival between RFCA combined with EI-VOM vs. RFCA alone in persistent AF patients and analyzed outcome predictors. Methods: Persistent AF patients were divided into EI-VOM combined with RFCA (EI-VOM + RFCA, Results: Freedom from atrial arrhythmia recurrence rates in the EI-VOM + RFCA group were significantly higher at all time points: 87.32% at 12 months, 80.25% at 24 months, and 77.46% at 36 months post-procedure. Corresponding rates in the RFCA alone group were lower: 78.05%, 65.85%, and 58.54%. Multivariate analysis identified receiving EI-VOM therapy and a smaller left atrial diameter as independent predictors of maintaining sinus rhythm long-term. Conclusion: Combining EI-VOM with standard RFCA significantly reduces atrial arrhythmia recurrence compared to RFCA alone in patients with persistent AF, demonstrating superior long-term effectiveness. EI-VOM is an independent predictor of successful sinus rhythm maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.